Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019...
LOS ANGELES--(BUSINESS WIRE)--Dec 13, 2019-- |!| Oelwein
LOS ANGELES--(BUSINESS WIRE)--Dec 13, 2019-- |!| Oelwein